HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

botulism immune globulin

in clinical trials; used to treat infant botulism; BIG-IV is an orphan drug Human Botulism Immune Globulin Intravenous which neutralizes botulinum toxin
Also Known As:
BIG-IV (botulism immune globulin)
Networked: 27 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Arnon, Stephen S: 7 articles (12/2018 - 02/2006)
2. Khouri, Jessica M: 3 articles (01/2018 - 04/2015)
3. Barash, Jason R: 2 articles (12/2018 - 04/2015)
4. Jewell, Nicholas P: 2 articles (01/2018 - 02/2006)
5. Payne, Jessica R: 2 articles (01/2018 - 01/2018)
6. Bonaffini, Sarah G: 1 article (12/2020)
7. Cocozza, Victoria: 1 article (12/2020)
8. Jin, Jing: 1 article (12/2020)
9. Castles, Joe B: 1 article (12/2018)
10. Centers for Disease Control and Prevention (CDC): 1 article (04/2015)

Related Diseases

1. Botulism
2. Toxemia
3. Paralysis (Palsy)
01/01/2003 - "Treatment is aimed at 1) maintaining respiration via intubation and mechanical ventilation, 2) stopping progression of weakness by administration of botulinum antitoxin (equine trivalent botulinum antitoxin for adults and botulism immune-globulin intravenous-human for infant botulism), and 3) preventing complications from weeks of paralysis with good supportive care. "
07/01/2023 - "Classically, the bulbar musculature is affected before somatic muscular, which results in the typical presentation of "descending paralysis."2,5 While confirmatory testing is important, it is often delayed by more than 24 hours, making both clinical recognition and implementation of treatment before confirmatory testing of vital importance.6,7 Treatment consists of providing airway, nutritional, and hydration support in addition to administering botulinum-specific antitoxin.8,9 While patients over the age of 12 months are treated with equine botulinum antitoxin, the Food and Drug Administration (FDA) has approved a human-derived immunoglobulin treatment, Botulism Immune Globulin Intravenous (BIG-IV, ie, "Baby BIG") for pediatric patients less than 12 months of age.1,2,6 Ordering BIG-IV is a complex and multidisciplinary process, requiring the treating physician to discuss any suspicious case with the Infant Botulism Treatment and Prevention Program (IBTPP) which is a branch of the California Department of Public Health.6 With early recognition and implementation of treatment, most infants will make a full recovery. "
4. Progressive Bulbar Palsy (Fazio Londe Syndrome)
5. Neuroblastoma

Related Drugs and Biologics

1. Botulinum Toxins (Botulinum Toxin)
2. botulinum toxin type F
3. Botulinum Antitoxin
4. Antitoxins
5. Immunoglobulins (Immunoglobulin)

Related Therapies and Procedures

1. Artificial Respiration (Mechanical Ventilation)
2. Length of Stay
3. Intravenous Administration
4. Bone Marrow Transplantation (Transplantation, Bone Marrow)
5. Therapeutics